Skip to main content
. 2020 Aug 18;15(8):e0232917. doi: 10.1371/journal.pone.0232917

Fig 5. Treatment with cRGDfK inhibits proliferation of human NSCLC cells.

Fig 5

(A) Chemical structure of cRGDfK. (B) The relative mRNA expression of integrin α and β3 in human NSCLC cells. (C‒F) NSCLC A549 (C), H1299 (D), and H358 (E) cells and normal fibroblast IMR90 cells (F) were treated with cRGDfK for 24‒72 h. After incubation, cell viability was measured by CCK-8 assay. Experiments were performed in triplicate. Data represent the mean ± SD of raw results.